Next Generation of Genetically Engineered NK Cells for Adoptive Immunotherapy

Time: 10:40 am
day: Day Two


• Treating solid tumors with off-the-shelf engineered aNK cell lines targeting PD-L1 immune checkpoint
• Improving activity against the tumor microenvironment through targeting of MDSCs and resistance to hypoxic conditions
• Targeting COVID-19 with off-the-shelf CD16-expressing NK cells and convalescent plasma